Bicara Therapeutics’ (BCAX) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock.

A number of other equities research analysts have also recently commented on the company. Citizens Jmp reissued a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Citigroup assumed coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating on the stock. Finally, Bank of America started coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $19.89 on Tuesday. The stock has a market cap of $1.09 billion, a PE ratio of -7.86 and a beta of -0.78. Bicara Therapeutics has a 1 year low of $7.80 and a 1 year high of $20.25. The firm has a fifty day moving average price of $17.21 and a 200-day moving average price of $16.67.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. On average, research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, insider David Raben sold 16,300 shares of Bicara Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the completion of the transaction, the insider directly owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This trade represents a 22.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Ivan Hyep sold 13,555 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 137,969 shares of company stock valued at $2,586,198.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BCAX. Bleakley Financial Group LLC bought a new stake in Bicara Therapeutics during the third quarter worth approximately $481,000. Cantor Fitzgerald L. P. bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $1,579,000. Schroder Investment Management Group lifted its stake in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after purchasing an additional 383,681 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Bicara Therapeutics by 160.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after purchasing an additional 61,201 shares during the period. Finally, SCS Capital Management LLC purchased a new position in shares of Bicara Therapeutics in the 2nd quarter worth approximately $496,000.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Phase‑3 advancement and clinical catalysts: Bicara selected a 1,500 mg weekly dose of ficerafusp alfa and has initiated the pivotal FORTIFI‑HN01 trial with interim Phase‑3 readout expected mid‑2027; long‑term Phase‑1b follow‑up is slated for ASCO 2026 — these program milestones underpin upside potential. Article Title
• Positive Sentiment: Corporate update & financials: Q4/FY‑2025 release highlighted a strong cash position, selection of the Phase‑3 dose, and a less‑frequent dosing regimen in development — gives runway to reach clinical milestones. Article Title
• Positive Sentiment: Strong buy-side analyst support from some firms: HC Wainwright reiterated a Buy and boosted its PT to $42; Citizens Jmp and Wedbush reaffirmed market/outperform views with $31 and $30 targets — these bulls can attract momentum buyers. Article Title
• Neutral Sentiment: Modest Q4 beat: Bicara reported EPS of ($0.68) vs. consensus ($0.72) — a small beat but still operating at losses as expected for a clinical‑stage biotech. Press Release
• Neutral Sentiment: Mixed mid‑range analyst moves: Goldman Sachs and Wells Fargo raised price targets to $16 but kept Neutral/Equal‑Weight ratings (their PTs sit below the current trading level), which tempers upside for cautious investors. Article Title
• Negative Sentiment: Insider sale: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings — a small insider sale but some investors view insider selling as a cautionary signal. Article Title

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.